4-溴噻吩-3-羰酰氯 | 72899-51-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 噻吩类
• 中文名称: 4-溴噻吩-3-羰酰氯
• 英文名称: 4-Bromo-thiophene-3-carbonyl chloride
• 英文别名: 4-Bromothiophene-3-carbonyl chloride
• CAS: 72899-51-5
• 化学式: C₅H₂BrClOS
• 分子量: 225.493
• InChiKey: RAEMKVHFZZHQSI-UHFFFAOYSA-N

物化性质

• 熔点：
  67.5-69°C
• 沸点：
  251.1±20.0 °C(Predicted)
• 密度：
  1.855±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.8
• 重原子数：
  9
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  45.3
• 氢给体数：
  0
• 氢受体数：
  2

安全信息

• 危险品标志：
  C
• 海关编码：
  2934999090
• 危险标志：
  GHS07
• 危险性描述：
  H319
• 危险性防范说明：
  P305 + P351 + P338

SDS

---

SECTION 1: Identification of the substance/mixture and of the company/undertaking
Product identifiers
Product name : 4-Bromothiophene-3-carbonyl chloride
: CBR01152
REACH No. : A registration number is not available for this substance as the substance
or its uses are exempted from registration, the annual tonnage does not
require a registration or the registration is envisaged for a later
registration deadline.
CAS-No. : 72899-51-5

---

SECTION 2: Hazards identification
Classification of the substance or mixture
Classification according to Regulation (EC) No 1272/2008
Eye irritation (Category 2), H319
For the full text of the H-Statements mentioned in this Section, see Section 16.
Classification according to EU Directives 67/548/EEC or 1999/45/EC
Xi Irritant R36
For the full text of the R-phrases mentioned in this Section, see Section 16.
Label elements
Labelling according Regulation (EC) No 1272/2008
Pictogram
Signal word Warning
Hazard statement(s)
Causes serious eye irritation.
Precautionary statement(s)
P305 + P351 + P338 IF IN EYES: Rinse cautiously with water for several minutes. Remove
contact lenses, if present and easy to do. Continue rinsing.
Supplemental Hazard none
Statements
Other hazards - none

---

SECTION 3: Composition/information on ingredients
Substances
Formula : C5H2BrClOS
Molecular Weight : 225,49 g/mol
CAS-No. : 72899-51-5
Hazardous ingredients according to Regulation (EC) No 1272/2008
Component Classification Concentration
4-Bromothiophene-3-carbonyl chloride
Eye Irrit. 2; H319 -
Hazardous ingredients according to Directive 1999/45/EC
Component Classification Concentration
4-Bromothiophene-3-carbonyl chloride
Xi, R36 -
For the full text of the H-Statements and R-Phrases mentioned in this Section, see Section 16

---

SECTION 4: First aid measures
Description of first aid measures
General advice
Consult a physician. Show this safety data sheet to the doctor in attendance.
If inhaled
If breathed in, move person into fresh air. If not breathing, give artificial respiration. Consult a physician.
In case of skin contact
Wash off with soap and plenty of water. Consult a physician.
In case of eye contact
Rinse thoroughly with plenty of water for at least 15 minutes and consult a physician.
If swallowed
Never give anything by mouth to an unconscious person. Rinse mouth with water. Consult a physician.
Most important symptoms and effects, both acute and delayed
The most important known symptoms and effects are described in the labelling (see section 2.2) and/or in
section 11
Indication of any immediate medical attention and special treatment needed
no data available

---

SECTION 5: Firefighting measures
Extinguishing media
Suitable extinguishing media
Use water spray, alcohol-resistant foam, dry chemical or carbon dioxide.
Special hazards arising from the substance or mixture
no data available
Advice for firefighters
Wear self contained breathing apparatus for fire fighting if necessary.
Further information
no data available

---

SECTION 6: Accidental release measures
Personal precautions, protective equipment and emergency procedures
Use personal protective equipment. Avoid breathing vapors, mist or gas. Ensure adequate ventilation.
For personal protection see section 8.
Environmental precautions
Do not let product enter drains.
Methods and materials for containment and cleaning up
Soak up with inert absorbent material and dispose of as hazardous waste. Keep in suitable, closed
containers for disposal.
Reference to other sections
For disposal see section 13.

---

SECTION 7: Handling and storage
Precautions for safe handling
Avoid contact with skin and eyes. Avoid inhalation of vapour or mist.
For precautions see section 2.2.
Conditions for safe storage, including any incompatibilities
Store in cool place. Keep container tightly closed in a dry and well-ventilated place. Containers which are
opened must be carefully resealed and kept upright to prevent leakage.
Specific end use(s)
A part from the uses mentioned in section 1.2 no other specific uses are stipulated

---

SECTION 8: Exposure controls/personal protection
Control parameters
Components with workplace control parameters
Exposure controls
Appropriate engineering controls
Handle in accordance with good industrial hygiene and safety practice. Wash hands before breaks and
at the end of workday.
Personal protective equipment
Eye/face protection
Safety glasses with side-shields conforming to EN166 Use equipment for eye protection tested
and approved under appropriate government standards such as NIOSH (US) or EN 166(EU).
Skin protection
Handle with gloves. Gloves must be inspected prior to use. Use proper glove removal technique
(without touching glove's outer surface) to avoid skin contact with this product. Dispose of
contaminated gloves after use in accordance with applicable laws and good laboratory practices.
Wash and dry hands.
The selected protective gloves have to satisfy the specifications of EU Directive 89/686/EEC and
the standard EN 374 derived from it.
Body Protection
Impervious clothing., The type of protective equipment must be selected according to the
concentration and amount of the dangerous substance at the specific workplace.
Respiratory protection
Where risk assessment shows air-purifying respirators are appropriate use a full-face respirator
with multi-purpose combination (US) or type ABEK (EN 14387) respirator cartridges as a backup
to engineering controls. If the respirator is the sole means of protection, use a full-face supplied air
respirator. Use respirators and components tested and approved under appropriate government
standards such as NIOSH (US) or CEN (EU).
Control of environmental exposure
Do not let product enter drains.

---

SECTION 9: Physical and chemical properties
Information on basic physical and chemical properties
a) Appearance Form: liquid
b) Odour no data available
c) Odour Threshold no data available
d) pH no data available
e) Melting point/freezing no data available
point
f) Initial boiling point and no data available
boiling range
g) Flash point no data available
h) Evaporation rate no data available
i) Flammability (solid, gas) no data available
j) Upper/lower no data available
flammability or
explosive limits
k) Vapour pressure no data available
l) Vapour density no data available
m) Relative density no data available
n) Water solubility no data available
o) Partition coefficient: n- log Pow: 2,216
octanol/water
p) Auto-ignition no data available
temperature
q) Decomposition no data available
temperature
r) Viscosity no data available
s) Explosive properties no data available
t) Oxidizing properties no data available
Other safety information
no data available

---

SECTION 10: Stability and reactivity
Reactivity
no data available
Chemical stability
Stable under recommended storage conditions.
Stable under recommended storage conditions.
Possibility of hazardous reactions
no data available
Conditions to avoid
no data available
Incompatible materials
Strong oxidizing agents
Hazardous decomposition products
Other decomposition products - no data available
In the event of fire: see section 5

---

SECTION 11: Toxicological information
Information on toxicological effects
Acute toxicity
no data available
Skin corrosion/irritation
no data available
Serious eye damage/eye irritation
no data available
Respiratory or skin sensitization
no data available
Germ cell mutagenicity
no data available
Carcinogenicity
IARC: No component of this product present at levels greater than or equal to 0.1% is identified as
probable, possible or confirmed human carcinogen by IARC.
Reproductive toxicity
no data available
Specific target organ toxicity - single exposure
no data available
Specific target organ toxicity - repeated exposure
no data available
Aspiration hazard
no data available
Additional Information
RTECS: Not available
To the best of our knowledge, the chemical, physical, and toxicological properties have not been
thoroughly investigated.

---

SECTION 12: Ecological information
Toxicity
no data available
Persistence and degradability
no data available
Bioaccumulative potential
no data available
Mobility in soil
no data available
Results of PBT and vPvB assessment
PBT/vPvB assessment not available as chemical safety assessment not required/not conducted
Other adverse effects
no data available

---

SECTION 13: Disposal considerations
Waste treatment methods
Product
Offer surplus and non-recyclable solutions to a licensed disposal company.
Contaminated packaging
Dispose of as unused product.

---

SECTION 14: Transport information
UN number
ADR/RID: - IMDG: - IATA: -
UN proper shipping name
ADR/RID: Not dangerous goods
IMDG: Not dangerous goods
IATA: Not dangerous goods
Transport hazard class(es)
ADR/RID: - IMDG: - IATA: -
Packaging group
ADR/RID: - IMDG: - IATA: -
Environmental hazards
ADR/RID: no IMDG Marine Pollutant: no IATA: no
Special precautions for user
no data available

---

SECTION 15: Regulatory information
This safety datasheet complies with the requirements of Regulation (EC) No. 1907/2006.
Safety, health and environmental regulations/legislation specific for the substance or mixture
no data available
Chemical Safety Assessment

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  4-溴噻吩-3-羰酰氯 在 2,6-二甲基吡啶 、 甲醇 、 sodium tetrahydroborate 、 四(三苯基膦)钯 、 三甲基乙酸钾 、 potassium carbonate 、 lithium chloride 作用下， 以 四氢呋喃 、 2-甲基四氢呋喃 、 5,5-dimethyl-1,3-cyclohexadiene 、 二氯甲烷 为溶剂， 反应 16.0h， 生成 ((5,5-dimethyl-5,6-dihydro-4H-cyclopenta[c]thiophen-4-yl)oxy)triisopropylsilane
  参考文献：
  名称：

  分子内钯（0）催化的C（sp3）合成1-茚满醇和1-茚满胺？高度化：构象效应的影响

  摘要：

  尽管存在不利的空间相互作用，但通过分子内钯（0）催化的C（sp 3）H芳基化反应合成了一系列含有叔C1原子的有价值的1-茚满醇和1-茚满胺。正如索普-英戈尔德效应所预期的那样，发现反应的效率与C2处的取代度有关。此外，C1上的杂原子取代基的性质对C1和C2上的非对映选择性有显着影响；实际上，获得了1-茚满醇和1-茚满胺，它们具有相反的相对构型。对相应的反应中间体进行X射线和DFT优化结构的分析，为深入了解这些取代基引起的微妙构象效应提供了有用的见识。

  DOI：

  10.1002/chem.201402907
• 作为产物：
  描述：

  4-溴噻吩-3-羧酸 在 草酰氯 作用下， 以 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 生成 4-溴噻吩-3-羰酰氯
  参考文献：
  名称：

  几种新型杂环香芹酚酯的合成及生物学评价

  摘要：

  在这项工作中，通过香芹酚与杂环羧酸的缩合合成了五种新型酯（ ​​E4、E5、E6、E7和E8 ）。新合成的化合物的结构通过FT-IR和1 H-NMR分析进行了鉴定。筛选了新的基于香芹酚的化合物及其原始天然产物（香芹酚）对各种细菌和癌细胞的体外生物活性。结果表明，酯E4对所有研究类型的细菌均具有较强的抑制作用，其中对革兰氏阴性菌肺炎克雷伯菌的MIC为62.5μg/mL的酯E4比MIC为125μg/mL的香芹酚更有效。

  DOI：

  10.1016/j.molstruc.2023.136599

文献信息

• Dual Role of Rh(III) Catalyst Enables Regioselective Halogenation of (Electron-Rich) Heterocycles
  作者：Nils Schröder、Fabian Lied、Frank Glorius

  DOI：10.1021/jacs.5b00283

  日期：2015.2.4

  The Rh(III)-catalyzed selective bromination and iodination of electron-rich heterocycles is reported. Kinetic investigations show that Rh plays a dual role in the bromination, catalyzing the directed halogenation and preventing the inherent halogenation of these substrates. As a result, this method gives highly selective access to valuable halogenated heterocycles with regiochemistry complementary

  报道了 Rh(III) 催化的富电子杂环的选择性溴化和碘化。动力学研究表明，Rh 在溴化中起着双重作用，催化定向卤化并防止这些底物的固有卤化。因此，该方法可以高度选择性地获取有价值的卤化杂环，其区域化学与使用未催化方法获得的那些互补，后者依赖于这些类别底物的固有反应性。可以应用呋喃、噻吩、苯并噻吩、吡唑、喹诺酮和色酮。
• [EN] IMIDAZOPYRIDINES AS A NOVEL SCAFFOLD FOR MULTI-TARGETED KINASE INHIBITION<br/>[FR] IMIDAZOPYRIDINES UTILISÉES COMME NOUVEL ÉCHAFAUDAGE POUR L'INHIBITION DES KINASES À CIBLES MULTIPLES
  申请人：ABBOTT LAB

  公开号：WO2011053476A1

  公开（公告）日：2011-05-05

  Compounds that inhibit protein kinases, compositions containing the compounds and methods of treating diseases using the compounds are disclosed. Formula (I).

  抑制蛋白激酶的化合物，含有这些化合物的组合物以及使用这些化合物治疗疾病的方法被披露。公式（I）。
• Palladium-catalyzed intramolecular C–H arylation of 2-halo-<i>N</i>-Boc-<i>N</i>-arylbenzamides for the synthesis of N–H phenanthridinones
  作者：Quan-Fang Hu、Tian-Tao Gao、Yao-Jie Shi、Qian Lei、Luo-Ting Yu

  DOI：10.1039/c8ra02099j

  日期：——

  A palladium catalyzed synthesis of N–H phenanthridinones was developed via C–H arylation. The protocol gives phenanthridinones regioselectively by one-pot reaction without deprotection. It exhibits broad substrate scope and affords targets in up to 95% yields. Importantly, it could be applied for the less reactive o-chlorobenzamides.

  通过C-H 芳基化开发了钯催化的 N-H 菲啶酮合成。该协议通过一锅反应区域选择性地提供菲啶酮，而无需去保护。它表现出广泛的底物范围，并以高达 95% 的产率提供目标。重要的是，它可以应用于反应性较低的邻氯苯甲酰胺。
• A Convenient Approach to Heterocyclic Building Blocks: Synthesis of Novel Ring Systems Containing a [5,6]Pyrano[2,3-c]pyrazol-4(1H)-one Moiety
  作者：Gernot Eller、Wolfgang Holzer

  DOI：10.3390/12010060

  日期：——

  6]pyrano[2,3-c]pyrazol-4(1H)-one, thieno[3',2':5,6]pyrano[2,3c]pyrazol- 4-(1H)-one, thieno[3',4':5,6]pyrano[2,3-c]pyrazol-4(1H)-one, thieno[3'',2'':4',5']thieno[2',3':5,6]-pyrano[2,3-c]pyrazol-4(1H)-one, [1,3]dioxolo[5',6'][1]benzothieno[2',3':5,6]pyrano-[2,3-c]- pyrazol-4(1H)-one, pyridazino[4',3':5,6]pyrano[2,3-c]pyrazol-4(1H)-one and pyrazolo-[4'',3'':5',6']pyrido[3',4':5,6]pyrano[2,3-c]pyrazol-4(1H)-one

  从可商购的离析物开始，通向三环，四环或五环体系的一步或两步合成是向新杂环构件的直接合成路线。以下新型环系统的代表是由3-甲基-1-苯基-2-吡唑啉-5-酮和相应的邻卤代芳烃羰基氯在回流的1,4-二恶烷中使用氢氧化钙制备的：嘧啶[4'， 5'：5,6] pyrano [2,3-c] pyrazol-4（1H）-one，thieno [3'，2'：5,6] pyrano [2,3c] pyrazol- 4-（1H）-一，thieno [3'，4'：5,6] pyrano [2,3-c] pyrazol-4（1H）-one，thieno [3''，2''：4'，5'] thieno [2 '，3'：5,6]-吡喃并[2,3-c]吡唑-4（1H）-one，[1,3] dioxolo [5'，6'] [1] benzothieno [2'，3' ：5,6] pyrano- [2,3-c]-pyraz
• Synthesis and Antitumour Activity of New Derivatives of Flavone-8-acetic Acid (FAA). Part 31): 2-Heteroaryl Derivatives
  作者：R. Alan Aitken、Michael C. Bibby、Florian Bielefeldt、John A. Double、Andrea L. Laws、Anne-Laure Mathieu、Robert B. Ritchie、David W. J. Wilson

  DOI：10.1002/(sici)1521-4184(199812)331:12<405::aid-ardp405>3.0.co;2-2

  日期：1998.12

  A range of 14 derivatives of flavone‐8‐acetic acid (FAA) with a heterocyclic substituent in place of the 2‐phenyl group have been prepared and their anti‐tumour activity evaluated in vitro against a panel of human and murine tumour cell lines and in vivo against MAC 15A. Some of the compounds, notably 2c, d and s, showed significant in vivo activity and these require further studies in order to evaluate

  已经制备了一系列 14 种黄酮 - 8 - 乙酸 (FAA) 衍生物，其中杂环取代基取代了 2 - 苯基，并在体外针对一组人和鼠肿瘤细胞系评估了它们的抗肿瘤活性和在体内针对 MAC 15A。一些化合物，特别是 2c、d 和 s，显示出显着的体内活性，这些需要进一步研究以评估其发展潜力。